---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-024914"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T22:05:10.592033+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lilly to supply additional 150K doses of AbCellera's bebtelovimab for ~$275M

## Summary
- Eli Lilly modified agreement with U.S. government for 150,000 additional doses of bebtelovimab at ~$275M.
- Delivery begins immediately and completes by August 5, 2022; option for 350,000 more doses by Sep 14, 2022.
- Bebtelovimab maintains neutralization against Omicron variants BA.2.12.1 and BA.4/BA.5, plus all known variants.
- Existing supply plus new purchase expected to meet U.S. demand through late August 2022.

## SEC filing metadata
- accession: 0001564590-22-024914
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022024914/0001564590-22-024914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022024914/abcl-8k_20220629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-024914
- JSON: https://secwatch.observer/filing/0001564590-22-024914.json
- Plain text: https://secwatch.observer/filing/0001564590-22-024914.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.